Document Detail

Testicular dysfunction in Hodgkin's disease before and after treatment.
MedLine Citation:
PMID:  1835853     Owner:  NLM     Status:  MEDLINE    
Over a 7-year period, semen analysis was performed in 92 male patients with Hodgkin's disease prior to therapy. In 67% of patients semen revealed a decreased chance for fertility (i.e. oligozoospermia, asthenozoospermia and/or teratozoospermia). The mean basal levels of follicle-stimulating hormone (FSH), luteinising hormone, testosterone and prolactin were in the normal range. In 77 patients in complete remission after alternating MOPP/ABVD (mechlorethamine, vincristine, procarbazine, prednisone; doxorubicin, bleomycin, vinblastine, dacarbazine), testicular function was assessed. 87% of patients were azoospermic, 9% had semen abnormalities and only 4% were normospermic. Recovery of spermatogenesis was documented in only 17 of 42 (40%) reassessed patients after a median time of 27 months and was generally not affected by pretreatment sperm quality. After chemotherapy, the mean value of FSH [20.45 (S.E. 1.7) mUI/ml] was significantly superior compared with that of the mean pretreatment values. No difference was documented in the mean testosterone and prolactin values tested before and after treatment. Our findings indicate that, of patients with Hodgkin's disease, about half are affected by hypogonadism before starting chemotherapy. By utilising alternating MOPP/ABVD, persistent testicular dysfunction was documented in half of the patients.
S Viviani; G Ragni; A Santoro; L Perotti; E Caccamo; E Negretti; P Valagussa; G Bonadonna
Related Documents :
21786273 - Graves' orbitopathy: extraocular muscle/total orbit area ratio is positively related to...
6733403 - Ultrasonic detection of occult testicular neoplasms in patients with gynaecomastia.
21789553 - Cavernous vessels around a patent portal trunk in the liver hilum.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  27     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1991  
Date Detail:
Created Date:  1992-01-16     Completed Date:  1992-01-16     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1389-92     Citation Subset:  IM    
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Follicle Stimulating Hormone / blood
Hodgkin Disease / blood,  drug therapy*
Luteinizing Hormone / blood
Oligospermia / chemically induced
Prolactin / blood
Sperm Motility / drug effects
Spermatogenesis / drug effects*
Testicular Diseases / chemically induced*
Testosterone / blood
Reg. No./Substance:
58-22-0/Testosterone; 9002-62-4/Prolactin; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Paternity in patients with testicular germ cell cancer: pretreatment and post-treatment findings.
Next Document:  Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitr...